You may not notice any vision changes with background diabetic retinopathy. Treatment isn't needed, but improving blood sugar levels can help prevent this diabetes complication from getting worse.

Background retinopathy is said to occur if you have developed microaneurysms on your retina. Microaneurysms are when there is a swelling of the capillaries (very small blood vessels) that feed the ...

If you have diabetes, you may get a condition called diabetic retinopathy. It’s the most common cause of vision loss among people with diabetes. WebMD explains the stages of this disease and how ...

Nonproliferative retinopathy is also known as background retinopathy. During the early stages of retinopathy, you might not notice problems with your vision, but your eye doctor will usually be ...

Background Retinopathy . The first stage of the disease is background retinopathy, which is characterized by the appearance of microaneurysms in the blood vessels of the eyes.

Background retinopathy. Your blood vessels are damaged, but you can still see OK. It can get worse if you don't manage your diabetes well. Maculopathy. This occurs when diabetes affects the macula.

Retinopathy can lead to blindness but the good news is that it can be treated, especially if retinopathy progression is caught at an early stage. It is likely that if you have had diabetes for a ...

Diabetic retinopathy can take two forms, background retinopathy and proliferative retinopathy. During the early stage of the disease (background retinopathy), small blood vessels in the retina leak a ...

In addition to 'Background diabetic retinopathy', there may be other similar symptoms or signs that better match your side effect. These have also been listed below for your convenience.

Pre-existing Diabetic Retinopathy and COVID-19 Outcomes. ... Diabetic retinopathy was reported in 67 (36%) patients, of whom 80% had background retinopathy and 20% had more advanced retinopathy.

A Phase 3 clinical trial, PANORAMA, evaluating Regeneron Pharmaceuticals' (NASDAQ:REGN) EYLEA (aflibercept) in patients with moderately severe and severe non-proliferative diabetic retinopathy ...

The occurrence of any retinopathy or maculopathy progression was also significantly less common with fenofibrate, 32.1% vs 40.2% with placebo (hazard ratio [HR], 0.74), as was referral for ...